Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Latanoprost is a derivative of prostaglandin F2α (PGF2α; Item Nos. 16010 | 16020), an FP receptor agonist, and a prodrug of latanoprost (free acid) (Item No. 16811).1 It induces phosphoinositide turnover in isolated human ciliary muscle and human trabecular meshwork cells, HEK293 cells expressing human ocular FP receptors, mouse NIH3T3 fibroblasts, and rat A7r5 vascular smooth muscle cells (EC50s = 313, 564, 173, 142, and 110 nM, respectively). Topical ocular application of latanoprost (0.005% twice per day) reduces intraocular pressure (IOP), without affecting outflow facility or aqueous humor flow rates, in cynomolgus monkeys in a model of laser-induced glaucoma.2 Formulations containing latanoprost have been used in the treatment of open-angle glaucoma or ocular hypertension.
WARNING This product is not for human or veterinary use.
1. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19(6), 501-515 (2003).
2. A comparative study of latanoprost (Xalatan) and isopropyl unoprostone (Rescula) in normal and glaucomatous monkey eyes. Jpn. J. Ophthalmol. 42(2), 95-100 (1997).
The effects of prostaglandin analogues on IOP in prostanoid FP-